For the quarter ending 2025-09-30, ENTO had $2,505,739 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -1,152,810 | -2,257,890 |
| Change in right-of-use assets | 0 | 17,994 |
| Impairment of right-of-use assets | 0 | 108,759 |
| Prepaid expenses | -45,984 | -1,160 |
| Lease liabilities | 0 | -4,925 |
| Deposits | -1 | -49,129 |
| Accounts payable | 176,463 | 339,199 |
| Accrued expenses | -5,120 | 163,396 |
| Other liabilities | 79,795 | 709,665 |
| Net cash used in operating activities | -855,688 | -873,513 |
| Cash acquired in acquisition of imgx | 336,427 | - |
| Net cash provided by investing activities | 336,427 | - |
| Proceeds from issuance of common stock, prefunded warrants and warrants, net | 3,025,000 | - |
| Proceeds from line of credit | 0 | 700,000 |
| Net cash provided by financing activities | 3,025,000 | 700,000 |
| Net (decrease) in cash, cash equivalents and restricted cash | 2,505,739 | -173,513 |
| Cash and cash equivalents at beginning of period | 184,992 | - |
| Cash and cash equivalents at end of period | 2,517,218 | - |
Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. (ENTO)